Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
Fabrice Balavoine, Michel Azizi, Damien Bergerot et al. · Clinical Pharmacokinetics · 2013
Cited by 59 works. doi:10.1007/s40262-013-0125-y
Authors
- Fabrice Balavoine
- Michel Azizi
- Damien Bergerot
- Nadia De Mota
- Rémi Patouret
- Bernard Pierre Roques
- Catherine Llorens‐Cortés
References
- Heart Disease and Stroke Statistics—2013 Update
- Applied pharmacokinetics : principles of therapeutic drug monitoring
- Angiotensin Synthesis in the Brain and Increased Turnover in Hypertensive Rats
- Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition
- Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.
- Copeptin: clinical use of a new biomarker
- Regulatory role of brain angiotensins in the control of physiological and behavioral responses
- Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
- Angiotensin-Converting Enzyme Gene Polymorphism Has No Influence on the Circulating Renin-Angiotensin-Aldosterone System or Blood Pressure in Normotensive Subjects
- Aminopeptidase A inhibitors as potential central antihypertensive agents